Compare Gilead Sciences, Inc. (GILD) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Gilead Sciences, Inc. trades at $136.01 (market cap $168.35B), while Direxion Daily Semiconductor Bear 3X Shares trades at $39.64. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.
| GILD | SOXS | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $1.49K |
52-Week Low | $110.56 | $32.50 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
SOXS, a leveraged inverse ETF tracking the semiconductor sector, trades at $39.56, down 12.5% in the past 24 hours amid a bearish technical signal. The stock split 1:10 on July 15, 2026, and paid a $0.04 dividend in June 2026. Technical indicators show oversold conditions with an RSI of 26.30, while moving averages signal a downtrend.
The outlook remains highly speculative due to SOXS's inverse leverage structure, which amplifies losses in rising markets. Risks include semiconductor sector volatility and the ETF's decay from daily rebalancing. It suits only aggressive traders betting against chip stocks, not long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
